Patient Alert Card for ADZYNMA®▼
(recombinant ADAMTS13 [rADAMTS13])

Important Information about ADZYNMA®

This patient alert card contains important safety information that you need to be aware of when you are using ADZYNMA®.

- **Always carry this alert card** with you while you are receiving treatments with rADAMTS13.
- **Show this card** to all emergency and healthcare providers.

HPRA date of approval: DEC-2024 Version 1.0

Patient's name:
Physician's name:
Physician's contact telephone number:

Reporting suspected side effects

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get via HPRA Pharmacovigilance, website: www.hpra.ie.

Adverse events can also be reported to Takeda at AE.GBR-IRL@takeda.com or via phone call to Takeda UK Ltd - 0044 3333 000 181 or Takeda Products Ireland Ltd – 1800 937 970 (freephone from Ireland only)

Information for Healthcare Professionals

This patient is being treated with rADAMTS13, an enzyme replacement therapy (ERT) indicated for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).

- Hypersensitivity reactions can occur during or after infusing rADAMTS13.
- Should the patient experience any of the hypersensitivity symptoms described below, treat the patient accordingly and contact the physician who prescribed rADAMTS13 to the patient.

Please read your rADAMTS13 package leaflet or talk to your doctor for more information about the side effects. This card will provide information about hypersensitivity reactions that may occur with the use of rADAMTS13. Not all possible side effects with the use of rADAMTS13 are listed on this card.

Important Information for patients/caregivers

rADAMTS13 is an enzyme replacement therapy (ERT) and has been given to you for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP).

Please remember:

rADAMTS13 may cause an allergic reaction called hypersensitivity. If you experience any of the following signs of hypersensitivity while taking rADAMTS13, the infusion should be stopped immediately and contact your doctor:

- Fast heart rate
- Tightness of the chest
- Wheezing and/or sudden onset of difficulty in breathing
- Low blood pressure
- Hives, rash and itchy skin
- Runny nose or nasal congestion
- Red eyes

- Sneezing
- Tiredness
- Rapid swelling under the skin in areas such as the face, throat, arms and legs
- Nausea (feeling sick)
- Vomiting
- Sensations like numbness, tingling, pins and needles
- Restlessness
- **Severe allergic reaction** (also called an anaphylactic reaction) can cause difficulty in swallowing and/or breathing, red or swollen face and/or hands

If symptoms of severe allergic reaction occur, immediately stop the use of rADAMTS13 and seek immediate emergency medical attention

Scan QR code or follow link
https://axian.link/adz-pat-IRL
to access the Patient website.

These materials are also available via the www.medicines.ie and www.hrpa.ie websites.